DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20185174

Adverse drug reactions associated with first line anti-tubercular drugs, their prevalence and causality assessment in patients on Directly Observed Treatment Short-course (DOTS) in a tertiary care hospital

Tauseef Nazir, Sameena Farhat, Mohd Adil, Zuryat Asraf

Abstract


Background: Treatment of tuberculosis involves giving multiple drugs to the patient which is done to prevent development of resistance besides targeting all bacterial sub-populations. The objective of the present study was to find out the adverse drug reactions (ADRs) of the first line anti-tubercular drugs and to calculate prevalence and causality of these drugs.

Methods: The study was conducted by the Department of Pharmacology, Government Medical College, Srinagar in association with the department of Chest medicine. All patients of tuberculosis on directly observed treatment-short course (DOTS) of either sex or age group were enrolled. An assessment of the causality and allocation of ADRs was done using Naranjo’s monitoring scale and WHO-UMC scale.

Results: A total of 57 ADRs with 13 different types were observed in 164 patients, with an overall prevalence of about 34.7%. Thirty seven (64.9%) ADRs were categorized as having a ‘probable’ causal relationship while 17 (29.8%) was categorized as ‘possible’ as per the Naranjo’s scale. As per the WHO-UMC monitoring scale fifty two (91.2%) were categorized as ‘possible’ while three (5.3%) were categorized as ‘certain’.

Conclusions: Occurrence of ADRs generally results in non-adherance. Timely detection of ADRs through an effective pharmacovigilance programme is the need of hour. The establishment of an active pharmacovigilance centre which was set up in our institution has paved the way to improve the quality of patient care by ensuring safer use of drugs and has helped us to identify and report the various ADR’s encountered.


Keywords


Adverse drug reactions, DOTS, Tuberculosis, WHO-UMC

Full Text:

PDF

References


WHO. International drug monitoring- the role of the national centres. Tech Rep ser WHO. No.; 1972:498.

Sinha K, Izora T, Asoka W. Adverse drug reactions in tuberculosis patients due to directly observed treatment strategy therapy. J Assoc Chest Physicians. 2013;1(2):50-3.

Bates DW, Spell N, Cullen DJ, Burdick E, Laird N, Petersen LA, et al. The costs of adverse drug events in hospitalized patients. JAMA. 1997 Jan 22;277(4):307-11.

Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients: excess length of stay, extra costs, and attributable mortality. JAMA. 1997 Jan 22;277(4):301-6.

Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000 Oct 7;356(9237):1255-9.

Wiffen P, Gill M, Edwards J, Moore A. Adverse drug reactions in hospital patients. A systematic review of prospective and retrospective studies. Bandolier Extra. 2002;2:1-16.

Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998 Apr 15;279(15):1200-5.

Centres for disease control and prevention. Tuberculosis: Data and statistics; 2017. Available at: https://www.cdc.gov/tb/statistics/default.htm. Accessed 01 November 2018.

Kumar V, Abbas AK, Fausto N, Mitchell RN. Robbins Basic Pathology. 8th ed. Saunders Elsevier; 2007;516-522.

Raval AA, Goswami H, Parikh U, Shah P, Yadav KS. Extra-pulmonary tuberculosis at tertiary health care center: a review. J Infect Dis Lett. 2013 Jan 1;2(1):16.

Verma R, Gr M, Shrivastava AK, Pathak P. Adverse drug reactions associated with first-line antitubercular drugs in a tertiary care hospital of central India: a study of clinical presentations, causality, and severity. Asian J Pharm Clin Res. 2014;7(5):140-3.

Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Therapeut. 1981 Aug 1;30(2):239-45.

WHO Handbook of resolutions and decisions of the world Health Assembly and Executive Board. 11th ed. Geneva, World Health Organizations, 1971-72. WHA 20.51.

Sharma A, Kansal D, Katoch K, Sharma PK, Bansal R, Sharma T. Pattern of adverse drug reactions in new smear positive patients of pulmonary tuberculosis treated under directly observed treatment short course. Int J Basic Clin Pharmacol. 2017 Jan 5;5(4):1397-401.

Sinha K, Marak IT, Singh WA. Adverse drug reactions in tuberculosis patients due to directly observed treatment strategy therapy: Experience at an outpatient clinic of a teaching hospital in the city of Imphal, Manipur, India. J Assoc Chest Physicians. 2013 Jul 1;1(2):50.

Iyer SP, Umakumar K, Mahajan A. Impact of HIV Infection on Outcome of Abdominal Tuberculosis. Bombay Hospital J. 2008;50(4):553-9.

Nazir A, Imam SF, Shabbir I, Saleem S. Adverse Drug Reactions of First Line Anti-tuberculosis Drugs used in DOTS Implemented Setting in Lahore. Pakistan J Med Res. 2015 Oct 1;54(4):101.

Hassan MK, Siddique A, Karadiya RK, Chakraborty A. Incidence of Adverse Drug Reaction Among the Tuberculosis Patients Treated Under Directly Observed Treatment Short course (DOTS) Regimen in North India. Indian J Applied Res. 2016;6(7):598-600.

Kurniawati F, Sulaiman SA, Gillani SW. Adverse drug reactions of primary anti-tuberculosis drugs among tuberculosis patients treated in chest clinic. Int J Pharmacy Life Sci. 2012 Jan 1;3(1):1331-8.

Dedun AR, Borisagar GB, Solanki RN. Impact of adverse drug reaction of first line anti-tuberculous drugs on treatment outcome of tuberculosis under revised national tuberculosis control programme. Int J Adv Med. 2017 May 23;4(3):645-9.

Ramanath KV, Ramesh SA. Study of assessment of adverse drug reactions in Tuberculosis patients. Am J Pharmtech Res. 2012;2(2).

Damasceno GS, Guaraldo L, Engstrom EM, Theme Filha MM, Souza-Santos R, et al. Adverse reactions to antituberculosis drugs in Manguinhos, Rio de Janeiro, Brazil. Clinics. 2013;68(3):329-37.

Athira B, Manju CS, Jyothi E. A study on adverse drug reactions to first line antitubercular drugs in DOTS therapy. Int J Pharmacol Clin Sci. 2015;4:7-11.

Puavilai S, Timpatanapong P. Prospective study of cutaneous drug reactions. Med Assoc Thai. 1989;72(3):167-71.

Wilson K. Sex-related differences in drug disposition in man. Clinpharmacokinest. 1984;9(3):189-202.

Sood A, Bansal R, Sharma A, Himani H, Bhagra S, Kansal D. Profile of adverse drug reactions in patients on anti-tubercular drugs in a sub Himalayan rural tertiary care teaching hospital. Int J Res Med Sci. 2016 Dec 19;4(10):4465-71.

Siribaddana A, Dissanayake KS, Athukorala GP, Pathirathne H, Senevirathna KP, Upul BA, et al. Frequency of adverse effects of fixed dose combinations, in tuberculosis and there effects on treatment outcome. SAARC J Tuberculosis Lung Dis HIV/AIDS. 2009;12(2):8-12.

Gholami K, Kamali E, Hajiabdolbaghi M, Shalviri G. Evaluation of anti-tuberculosis induced adverse reactions in hospitalized patients. Pharmacy Practice. 2006 Jul;4(3):134.